# Noetik

> Noetik is an AI-native biotechnology company building foundation models of human cancer biology to discover precision immunotherapies. It pairs one of the world's largest proprietary spatial-omics datasets - hundreds of millions of spatially resolved tumor and immune cells - with a high-throughput in vivo CRISPR Perturb-Map platform to train multimodal virtual cell models like OCTO-VC. These models simulate gene expression, cell states, and tumor-immune interactions, letting researchers find drug targets and predict patient response computationally. Founded in 2022 by former Recursion leaders Ron Alfa and Jacob Rinaldi, Noetik has raised roughly $62M and licenses its models to pharma, including an anchor partnership with GSK.

- **Founded:** 2022
- **Headquarters:** South San Francisco, California, United States
- **Founders:** Ron W. Alfa (Co-Founder & CEO (MD, PhD; formerly Recursion)), Jacob Rinaldi (Co-Founder & CSO (PhD; formerly Recursion))
- **Team size:** ~47 employees
- **Products:** OCTO-VirtualCell (OCTO-VC), Celleporter, Perturb-Map, Spatial cancer atlas, Model licensing / therapeutics pipeline
- **Notable:** Raised an oversubscribed $40M Series A in August 2024 (~$62M total funding), Released OCTO-VirtualCell, a ~1.5B-parameter virtual cell foundation model, and Celleporter in December 2024, Built one of the world's largest proprietary spatial-omics atlases (~200M tumor/immune cells across thousands of patients)

## Products & services

- **OCTO-VirtualCell (OCTO-VC)** — A ~1.5 billion parameter multimodal virtual cell foundation model trained on spatial proteomics, spatial transcriptomics, H&E pathology, DNA genotyping, and clinical metadata from nearly 200 million tumor and immune cells across thousands of patients. Simulates gene expression, cell states, and tumor-immune interactions.
- **Celleporter** — A companion visualization environment for exploring and interrogating outputs of the OCTO virtual cell models and spatial datasets.
- **Perturb-Map** — A high-throughput in vivo CRISPR perturbation platform that runs spatially resolved functional genomics experiments to generate causal training data for the foundation models.
- **Spatial cancer atlas** — One of the world's largest proprietary multimodal spatial-omics atlases of human cancer biology, comprising hundreds of millions of spatially resolved human cells.
- **Model licensing / therapeutics pipeline** — Licenses virtual cell foundation models to pharma partners and advances its own pipeline of precision immuno-oncology therapeutic candidates toward the clinic.

## Achievements

- Raised an oversubscribed $40M Series A in August 2024 (~$62M total funding)
- Released OCTO-VirtualCell, a ~1.5B-parameter virtual cell foundation model, and Celleporter in December 2024
- Built one of the world's largest proprietary spatial-omics atlases (~200M tumor/immune cells across thousands of patients)
- Signed an anchor model-licensing deal with GSK in January 2026 - cited as among the first and largest transactions monetizing a biological foundation model as an enterprise asset

## Latest updates

- **2026-01** — GSK licenses Noetik's OCTO-VC virtual cell foundation models in a five-year anchor partnership (~$50M upfront and near-term milestones plus annual license fees) covering NSCLC and colorectal cancer.
- **2025** — Agenus and Noetik enter collaboration to develop AI-enabled predictive biomarkers for the BOT/BAL immunotherapy combination using virtual cell foundation models.
- **2024-12** — Noetik announces OCTO-VirtualCell and Celleporter - foundation models of spatial biology for precision oncology.
- **2024-08** — Closes oversubscribed $40M Series A led by Polaris Partners.

## Links

- Website: https://noetik.ai
- LinkedIn: http://www.linkedin.com/company/noetik-inc
- Twitter/X: https://twitter.com/noetik_ai

---

Profile page: https://yespress.io/noetik
Published by YesPress — https://yespress.io
Last updated: 2026-06-13